Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis’ capmatinib gets FDA priority review in METex14 mutated advanced NSCLC
As per the new drug application (NDA) that has been accepted by the FDA, Novartis is seeking approval for the use of capmatinib as a treatment for first-line
As per the new drug application (NDA) that has been accepted by the FDA, Novartis is seeking approval for the use of capmatinib as a treatment for first-line
The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr.
Based on the result of the primary endpoint, Lilly has dropped its plan to pursue regulatory submission for solanezumab in people having dominantly inherited Alzheimer’s disease (DIAD) or
The Company also announced three new vaccine development candidates, which support the Company’s strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines
The late-stage trial called PANORAMA, which features 402 patients, has been assessing Eylea in comparison to sham injection for the improvement of moderately severe to severe NPDR without
In the study, 144 participants were randomized to receive either the vaccine or placebo to prevent recurrence. The vaccines were initiated within three months of completion of standard
This round was led by Forbion, with participation from BioMedPartners and founding investor BioGeneration Ventures (BGV). Azafaros was established in 2018 to translate innovative science from Leiden University
This collaboration will focus on the discovery of small molecule drug products to treat broad ranging allergies. Under the terms of the agreement, X-Chem will utilize its DEX
Recently declared as a global public health emergency by the World Health Organization (WHO), novel coronavirus had originated in the Chinese city of Wuhan. Regeneron is said to
The Centers for Disease Control and Prevention (CDC) has classified C. diff as an urgent public health threat, with limited options for treatment. RBX2660 was developed under Rebiotix’s